🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Panacea Biotec Limited PANACEABIO NSEPHARMA

Healthcare · Biotechnology · India
https://www.panaceabiotec.com
Company Profile ↓
₹543.55
+33.22% 1Y
Mkt Cap₹3,329.28 Cr
P/E-396.75
P/B4.22
52W High₹607.75
52W Low₹296.05
Book Value₹136.30
EPS (TTM)₹-1.37

Company Overview

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 27.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.9% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹639.77 Cr (+14.4% YoY); net profit ₹-5.37 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +14.4%, earnings -12.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.9%, profit CAGR 27.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.87%
1 Year:14.43%

Compounded Profit Growth

5 Years:27.95%
1 Year:-12.20%

Stock Price Performance

1 Year:+33.22%
6 Months:+33.81%
3 Months:+54.13%
1 Month:+0.51%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 79% of range
₹296.05 ₹607.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.28 · Neutral
Price Performance
1M+0.51%
3M+54.13%
6M+33.81%
1Y+33.22%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.9% over 5 years.
  • Profit CAGR of 27.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-396.75
Industry PE
39.97
Forward P/E
-
PEG Ratio
-
Book Value
₹136.30
Price to Book
4.22
P/S
5.49
EV/EBITDA
-65.87
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
11.87%
Profit 5Y
27.95%
Revenue (YoY)
14.43%
Earnings (YoY)
-12.20%

Profitability & Returns

ROCE
-0.14%
ROE
-0.64%
ROA
-0.43%
Profit Margin
-0.84%
Op Margin
-5.90%
Gross Margin
56.16%
EPS (Latest Qtr)
₹0.08
EPS (TTM)
₹-1.37

Balance Sheet & Liquidity

Debt/Equity
2.83
Quick Ratio
0.92
Current Ratio
1.47
Debt
₹23.66 Cr
Total Assets
₹1,262.17 Cr
Current Assets
₹513.04 Cr
Working Capital
₹164.36 Cr

Ownership

Promoter Holding
72.65%
Chg in Prom Hold
0.17%
FII / Inst Holding
0.13%
Chg in FII Hold
-3.43%

Financial Snapshot

Enterprise Value
₹3,329.28 Cr
Total Revenue (TTM)
₹639.77 Cr
EBITDA
₹31.74 Cr
Free Cash Flow
₹-37.41 Cr
Operating Cash Flow
₹16.68 Cr
Shares Outstanding
₹6.13 Cr
Gross Margin
56.16%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PANACEABIO Panacea Biotec Limited NSEPHARMA 543.55 -396.75 ₹3,329.28 Cr 0.00% -0.14% -0.64% 11.87% 27.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 128.93 Cr129.19 Cr143.02 Cr150.50 Cr136.46 Cr115.72 Cr147.35 Cr163.49 Cr132.53 Cr166.70 Cr141.13 Cr165.19 Cr166.75 Cr
Cost of Revenue --------52.08 Cr77.22 Cr58.94 Cr67.93 Cr76.39 Cr
Gross Profit --------80.45 Cr89.48 Cr82.19 Cr97.26 Cr90.36 Cr
Operating Expenses 134.60 Cr139.50 Cr146.58 Cr150.65 Cr142.50 Cr129.71 Cr140.35 Cr155.53 Cr115.75 Cr99.05 Cr108.32 Cr93.97 Cr95.67 Cr
Operating Income -15.18 Cr-19.79 Cr-12.87 Cr-9.26 Cr-14.85 Cr-22.72 Cr-1.68 Cr-1.02 Cr-35.30 Cr-9.57 Cr-26.13 Cr3.29 Cr-5.31 Cr
EBITDA -5.67 Cr-10.31 Cr-3.56 Cr-15.00 L-6.04 Cr-13.99 Cr7.00 Cr7.96 Cr9.42 Cr15.81 Cr-8.69 Cr16.79 Cr7.83 Cr
Interest Expense 1.05 Cr1.00 Cr91.00 L85.00 L82.00 L87.00 L98.00 L99.00 L1.04 Cr86.00 L2.14 Cr1.85 Cr1.20 Cr
Pretax Income 18.21 Cr13.03 Cr-7.78 Cr-1.65 Cr-2.12 Cr-17.05 Cr4.76 Cr4.38 Cr-4.00 L6.56 Cr-19.17 Cr6.49 Cr-1.25 Cr
Tax Provision 30.89 Cr2.05 Cr-51.04 L-54.99 L13.00 L1.17 Cr5.00 L-6.00 L1.95 Cr2.60 Cr-5.16 Cr2.60 Cr-25.00 L
Net Income -12.68 Cr10.98 Cr-8.29 Cr-2.20 Cr-1.99 Cr-15.88 Cr4.71 Cr4.44 Cr-1.89 Cr4.05 Cr-13.92 Cr3.98 Cr52.00 L
Diluted EPS -2.071.79-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.650.08

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 687.00 Cr653.00 Cr544.00 Cr593.00 Cr457.00 Cr544.00 Cr625.00 Cr-456.92 Cr551.93 Cr559.09 Cr639.77 Cr
Cost of Revenue --------278.76 Cr268.95 Cr199.54 Cr280.48 Cr
Gross Profit --------178.16 Cr282.98 Cr359.55 Cr359.29 Cr
Operating Expenses 643.00 Cr541.00 Cr505.00 Cr509.00 Cr591.00 Cr484.00 Cr548.00 Cr-283.81 Cr327.20 Cr420.27 Cr397.01 Cr
Operating Income -23.00 Cr39.00 Cr-29.00 Cr27.00 Cr-188.00 Cr17.00 Cr31.00 Cr--105.65 Cr-44.22 Cr-60.72 Cr-37.72 Cr
EBITDA 44.00 Cr112.00 Cr39.00 Cr84.00 Cr-134.00 Cr60.00 Cr77.00 Cr-55.73 Cr40.86 Cr30.74 Cr31.74 Cr
Interest Expense 105.00 Cr127.00 Cr101.00 Cr101.00 Cr105.00 Cr174.00 Cr185.00 Cr-3.80 Cr2.67 Cr3.88 Cr6.05 Cr
Pretax Income -99.00 Cr-19.00 Cr-67.00 Cr-66.00 Cr45.00 Cr-178.00 Cr-146.00 Cr-12.80 Cr1.48 Cr-7.95 Cr-7.37 Cr
Tax Provision -2.97 Cr-1.90 Cr10.72 Cr-9.90 Cr7.65 Cr-16.02 Cr-1.46 Cr-46.55 Cr2.98 Cr77.00 L-21.00 L
Net Income -108.00 Cr-21.00 Cr-56.00 Cr-76.00 Cr38.00 Cr-194.00 Cr-148.00 Cr--33.24 Cr-1.17 Cr-8.37 Cr-5.37 Cr
Diluted EPS -17.38-2.98-8.89-12.076.15-31.69-24.09176.05-5.43-0.19-1.37-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,930.00 Cr1,854.00 Cr1,789.00 Cr1,598.00 Cr1,376.00 Cr1,390.00 Cr1,178.00 Cr-1,271.17 Cr1,240.82 Cr1,289.75 Cr1,262.17 Cr
Current Assets --------568.32 Cr485.47 Cr545.18 Cr513.04 Cr
Cash & Equivalents --------39.85 Cr47.17 Cr82.12 Cr57.31 Cr
Inventory --------202.09 Cr177.94 Cr213.67 Cr192.79 Cr
Receivables --------60.09 Cr57.42 Cr72.56 Cr73.52 Cr
Total Liabilities --------431.05 Cr402.60 Cr459.13 Cr433.29 Cr
Current Liabilities --------331.83 Cr308.98 Cr366.99 Cr348.68 Cr
Long Term Debt --------20.16 Cr15.00 Cr15.00 Cr23.66 Cr
Total Debt 1,111.00 Cr1,105.00 Cr994.00 Cr941.00 Cr646.00 Cr742.00 Cr820.00 Cr-20.22 Cr15.00 Cr15.00 Cr23.66 Cr
Total Equity 455.00 Cr432.00 Cr356.00 Cr309.00 Cr350.00 Cr199.00 Cr-229.00 Cr-843.60 Cr842.05 Cr834.79 Cr834.84 Cr
Shares Outstanding --------6.13 Cr6.13 Cr6.13 Cr6.13 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 37.00 Cr91.00 Cr131.00 Cr118.00 Cr105.00 Cr-30.00 Cr107.00 Cr--422.45 Cr3.47 Cr-27.37 Cr16.68 Cr
Investing Cash Flow -37.00 Cr16.00 Cr-26.00 Cr55.00 Cr-6.00 Cr-35.00 Cr-48.00 Cr-430.33 Cr6.66 Cr64.98 Cr-40.49 Cr
Financing Cash Flow -1.00 Cr-117.00 Cr-107.00 Cr-164.00 Cr-101.00 Cr91.00 Cr-47.00 Cr--18.37 Cr-2.81 Cr-2.66 Cr-1.05 Cr
Capital Expenditure -7.00 Cr-6.00 Cr-24.00 Cr-15.00 Cr-5.00 Cr9.00 Cr-18.00 Cr--40.95 Cr-82.88 Cr-50.31 Cr-54.09 Cr
Free Cash Flow 30.00 Cr85.00 Cr107.00 Cr103.00 Cr100.00 Cr-21.00 Cr89.00 Cr--463.40 Cr-79.41 Cr-77.68 Cr-37.41 Cr
Net Change in Cash -1.00 Cr-10.00 Cr-2.00 Cr9.00 Cr-2.00 Cr26.00 Cr12.00 Cr--10.49 Cr7.32 Cr34.95 Cr-24.86 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------39.0%51.3%64.3%56.2%
Operating Margin % -3.3%6.0%-5.3%4.6%-41.1%3.1%5.0%--23.1%-8.0%-10.9%-5.9%
Net Margin % -15.7%-3.2%-10.3%-12.8%8.3%-35.7%-23.7%--7.3%-0.2%-1.5%-0.8%
ROE % -23.7%-4.9%-15.7%-24.6%10.9%-97.5%64.6%--3.9%-0.1%-1.0%-0.6%
ROCE % ---------11.2%-4.7%-6.6%-4.1%

Shareholding Pattern

Insiders
72.65%
Institutions
0.13%
Public Float
0.47%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PANACEABIO

Google News Fri, 09 Jan 2026

Panacea Biotec Limited (NSE:PANACEABIO) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQZFNnYjItdHB0WHY5UmMyVzlrOVczQ0MzYVRVa25KYzNqSVd1aXJwT0tGV1p4Y3ZJSVRTNGJSa0FyMUJBNG9MSUItQm9ER0lFNmVUNk9OMTlvdGJCckFIMC1PY3hncFR0eGwzeXVYdFRfNzhnWW9FQ3F5UTF2WlloVlhVXzhBaDBkM1VhSk…

Google News hu, 08 Jan 2026

Panacea Bio Share Price Jumps Nearly 6% As Dengue Vaccine Phase III Update Lifts Stock Market Today - Samco

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQTUZhTDEwT0lpNUljaFNCVEpWRDVPTTA1Y1luaDloNHpXeGhpRmxIOHJMSmdSX2lQZ3VNZ0RFUTFLVElUcXh4Z1ZiVld3ZDV2bVl2ZHJadG9Hc044bDVUU0s1SXRWeFBhaDR6RXFTeWdSd05URDNJakRiQTFzeVdhQ0VPZmJvQU9Lako4R2…

Google News Sat, 27 Dec 2025

Panacea Biotec Limited's (NSE:PANACEABIO) most bullish insider, CEO Rajesh Jain must be pleased with the recent 14% gain - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOLVBKMEJ4d3lETzhQRmE3TS15N2lTamVQdDlJZU9mejNiczhvWWdUX3FVcXp6RVhEa2sweFl2MERwYlROdEMtbHdydFE4SDNIdzNfd0ZnWjVfdllMTWg3UkpHV29TbnFBRkRwb0F0c2JNdFdrYTFZNXpfRGdudkV4VllrSVBFS3dIYzExaH…

Google News Fri, 19 Sep 2025

PANACEABIO Historical Data - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBkdUxjbmdWY25Xei1RMkl3OUlLV0w2bWpVSFJYV3lWOUs4RDhmZ0x2dkFEdGFncGtna0UwRy1lN2ZudG9GYUNfVVVXSWVPLWE0M3MzNi1pNFBMbXV1S3NFVkkzeUtGdw?oc=5" target="_blank">PANACEABIO Historical Data</a…

Google News Fri, 21 Nov 2025

Is Panacea Biotec (NSE:PANACEABIO) A Risky Investment? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPMEhIRzJ6OUpCQUtqcHFvV0UxeHZQNkZwTEZMY0dId0FYeVNRMk4wMEdqaHljVS1VR3ZWdTg3UU9WV0t4a1R0ZHhPLVVEcVd5cVhwc0xVNzAzRjVfcmQzb0xkMUxjeW1xUlNoOWhMeHJMOE10NUZXajlUV21PLUxoaHRvYXVZLWhhTjlfYU…

Google News Wed, 26 Jul 2017

PANACEABIO Stock Price and Chart — NSE:PANACEABIO - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE0xODdRcnl0WUtDY3RaUmpCOVFCUEFBcXh4Z1RvN2ItRGpEN3UzUi1aVVZqbmM3UFpTUDNET0c2V0N0MWdMU090al9PZERBOUdTTEcyem9YOHQ4bEFRR1ZhWg?oc=5" target="_blank">PANACEABIO Stock Price and Chart — NS…

PANACEABIO — Frequently Asked Questions

What is the current share price of Panacea Biotec Limited (PANACEABIO)?

As of 2026-07-15 09:52 IST, Panacea Biotec Limited (PANACEABIO) trades at ₹543.55 on NSE. Its 52-week range is ₹296.05 to ₹607.75.

What is the market capitalisation of PANACEABIO?

Panacea Biotec Limited (PANACEABIO) has a market capitalisation of ₹3,329.28 Cr on NSE.

What is the P/E ratio of PANACEABIO?

PANACEABIO trades at a trailing price-to-earnings (P/E) ratio of -396.75. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.22.

What is the return on equity (ROE) of PANACEABIO?

PANACEABIO has a return on equity (ROE) of -0.64%. Its return on capital employed (ROCE) is -0.14%.

Is PANACEABIO a good stock to buy?

This page provides a data-driven analysis of Panacea Biotec Limited (PANACEABIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space